0001209191-16-127439.txt : 20160613 0001209191-16-127439.hdr.sgml : 20160613 20160613172620 ACCESSION NUMBER: 0001209191-16-127439 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20160609 FILED AS OF DATE: 20160613 DATE AS OF CHANGE: 20160613 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ARCA biopharma, Inc. CENTRAL INDEX KEY: 0000907654 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 363855489 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 11080 CIRCLEPOINT ROAD STREET 2: SUITE 140 CITY: WESTMINSTER STATE: CO ZIP: 80020 BUSINESS PHONE: 720-940-2200 MAIL ADDRESS: STREET 1: 11080 CIRCLEPOINT ROAD STREET 2: SUITE 140 CITY: WESTMINSTER STATE: CO ZIP: 80020 FORMER COMPANY: FORMER CONFORMED NAME: NUVELO INC DATE OF NAME CHANGE: 20030203 FORMER COMPANY: FORMER CONFORMED NAME: HYSEQ INC DATE OF NAME CHANGE: 19970610 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: BRISTOW MICHAEL R CENTRAL INDEX KEY: 0001266125 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-22873 FILM NUMBER: 161711530 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2016-06-09 0 0000907654 ARCA biopharma, Inc. ABIO 0001266125 BRISTOW MICHAEL R 11080 CIRCLEPOINT ROAD SUITE 140 WESTMINSTER CO 80020 1 1 0 0 Pres. & Chief Executive Offic Common Stock 44610 D Common Stock 19986 I By InvestocorTrust as sole Trustee Common Stock 25459 I By NFS Custodian for Michael Bristow's IRA Stock Option (right to buy) 3.30 2016-06-09 4 A 0 27200 0.00 A 2026-06-08 Common Stock 27200 27200 D Stock Option (right to buy) 3.30 2016-06-09 4 A 0 55400 0.00 A 2026-06-08 Common Stock 55400 55400 D Includes (i) remaining 5,952 previously reported shares issued as RSUs under the Plan that vests on 9/17/16, (ii) remaining 4,050 previously reported shares issued as RSUs under the Plan that vest in two equal annual installments beginning on 2/27/17, and (iii) 4,581 previously reported shares issued as RSUs under the Plan that vest in two equal annual installments beginning 4/2/17, provided that the Reporting Person's continuous service to the Issuer has not been terminated as defined under the Plan; and 30,027 previously reported shares of common stock held directly. Grant to the Reporting Person of a stock option under the Plan, vesting in 36 equal monthly installments from the date of grant, provided that the Reporting Person's continuous service to the Issuer has not been terminated as defined in or as determined under the Plan prior to such time. In the event of a change in control of the Issuer, 50% of the unvested options shall become fully and immediately vested upon the closing date of such change in control, provided, however, that on the earlier of (i) the one-year anniversary of the closing date or (ii) involuntary termination, any options that remain unvested on such earlier date shall become fully and immediately vested. Grant to the Reporting Person of a stock option under the Plan, vesting upon achievement of certain pre-specified corporate milestones related to enrollment for the GENETIC-AF clinical trial, and the timing and outcome of the interim data analysis by that trial's Data and Safety Monitoring Board, provided that the Reporting Person's continuous service to the Issuer has not been terminated as defined in or as determined under the Plan prior to such time. If the corporate milestones are not achieved, the Option will be cancelled. In the event of a change in control of the Issuer, 50% of the unvested options shall become fully and immediately vested upon the closing date of such change in control, provided, however, that on the earlier of (i) the one-year anniversary of the closing date or (ii) involuntary termination, any options that remain unvested on such earlier date shall become fully and immediately vested. /s/ Brian L. Selby, Attorney-in-Fact 2016-06-13